Is the price fair?
What SHC's price assumes
Sotera Health Company trades at 34.3× earnings against 35.3× for the median Diagnostics & Research name, cheaper than its own group.
34.3
Trailing P/E · Diagnostics & Research median 35.3 · cheaper than the typical name in its group
- Price / sales
- 3.47
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.5%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +15%
Growth the price implies · The price pays for +15% free cash flow growth a year for a decade; revenue has grown +7.6% a year over the last three.
Details›
- Price / book2026-Q1
- 6.63
- EV / sales2026-Q1
- 5.00
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $113M
- Market capitalisation
- $4.51B
- 3-year revenue growth
- +7.6%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #18 of 29 by Smart Score